Last reviewed · How we verify
ROPINIROLE HYDROCHLORIDE
At a glance
| Generic name | ROPINIROLE HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
Common side effects
Key clinical trials
- Infusion of Apomorphine: Long-term Safety Study (PHASE3)
- Gait Analysis in Neurological Disease
- Impact of Switching to Continuous Release Dopamine Agonists (PHASE3)
- Exercise Training Versus Ropinirole in Treating Restless Legs Syndrome Among Hemodialysis Patients (NA)
- Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole (PHASE1, PHASE2)
- Butrans for Treatment of Restless Legs Syndrome (PHASE4)
- Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole (PHASE1, PHASE2)
- Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ROPINIROLE HYDROCHLORIDE CI brief — competitive landscape report
- ROPINIROLE HYDROCHLORIDE updates RSS · CI watch RSS